Norgine Holds Out Cetilistat Hope As Takeda Alliance Ends In Challenging Japan Market
Takeda and Norgine’s decision to finally end their alliance for cetilistat in Japan, years after the obesity drug was approved in its first potential market, serves as another sign of the sector’s challenges in the country.
You may also be interested in...
Deal through Kite Pharma subsidiary focuses on developing gamma delta T-cell receptor therapies. Sanofi inks SHP2 cancer collaboration with Revolution, while Vical considers its strategic options.
Beware the Ides of March, especially if you're an investor in the obesity drug market. Orexigen added further evidence that the market is crumbling as it hitched its wagon to a partner that is even worse off.
Takeda and Amylin Pharmaceuticals have decided formally to end their October 2009 global agreement for the co-development and co-commercialization of compounds for obesity.